LivaNova PLC (LIVN)
LIVN Stock Price Chart
Explore LivaNova PLC interactive price chart. Choose custom timeframes to analyze LIVN price movements and trends.
LIVN Company Profile
Discover essential business fundamentals and corporate details for LivaNova PLC (LIVN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
19 Oct 2015
Employees
3.30k
Website
https://www.livanova.comCEO
Vladimir A. Makatsaria
Description
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
LIVN Financial Timeline
Browse a chronological timeline of LivaNova PLC corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is $1.08, while revenue estimate is $380.53m.
Earnings released on 6 May 2026
EPS came in at $0.98 surpassing the estimated $0.85 by +15.29%, while revenue for the quarter reached $362.30m , beating expectations by +4.69%.
Earnings released on 25 Feb 2026
EPS came in at $0.86 surpassing the estimated $0.80 by +7.50%, while revenue for the quarter reached $360.90m , beating expectations by +2.15%.
Earnings released on 5 Nov 2025
EPS came in at $1.11 surpassing the estimated $0.92 by +20.78%, while revenue for the quarter reached $357.80m , beating expectations by +4.40%.
Earnings released on 6 Aug 2025
EPS came in at $1.05 surpassing the estimated $0.84 by +25.00%, while revenue for the quarter reached $352.50m , beating expectations by +6.10%.
Earnings released on 7 May 2025
EPS came in at $0.88 surpassing the estimated $0.75 by +17.33%, while revenue for the quarter reached $316.90m , beating expectations by +4.79%.
Earnings released on 25 Feb 2025
EPS came in at $0.81 surpassing the estimated $0.80 by +1.25%, while revenue for the quarter reached $321.80m , beating expectations by +4.26%.
Earnings released on 30 Oct 2024
EPS came in at $0.90 surpassing the estimated $0.71 by +26.76%, while revenue for the quarter reached $318.12m , missing expectations by -1.71%.
Earnings released on 31 Jul 2024
EPS came in at $0.93 surpassing the estimated $0.79 by +17.72%, while revenue for the quarter reached $318.58m , beating expectations by +4.72%.
Earnings released on 1 May 2024
EPS came in at $0.73 surpassing the estimated $0.45 by +62.22%, while revenue for the quarter reached $294.91m , missing expectations by -3.06%.
Earnings released on 21 Feb 2024
EPS came in at $0.87 surpassing the estimated $0.79 by +10.13%, while revenue for the quarter reached $310.10m , beating expectations by +7.90%.
Earnings released on 1 Nov 2023
EPS came in at $0.73 surpassing the estimated $0.62 by +17.74%, while revenue for the quarter reached $286.10m , beating expectations by +4.64%.
Earnings released on 26 Jul 2023
EPS came in at $0.78 surpassing the estimated $0.58 by +34.48%, while revenue for the quarter reached $293.90m , beating expectations by +8.09%.
Earnings released on 3 May 2023
EPS came in at $0.43 surpassing the estimated $0.41 by +4.88%, while revenue for the quarter reached $263.40m , beating expectations by +8.21%.
Earnings released on 22 Feb 2023
EPS came in at $0.81 surpassing the estimated $0.72 by +12.50%, while revenue for the quarter reached $274.90m , beating expectations by +4.81%.
Earnings released on 2 Nov 2022
EPS came in at $0.58 surpassing the estimated $0.57 by +1.75%, while revenue for the quarter reached $252.61m , beating expectations by +2.27%.
Earnings released on 3 Aug 2022
EPS came in at $0.53 surpassing the estimated $0.51 by +3.92%, while revenue for the quarter reached $254.20m , beating expectations by +1.86%.
Earnings released on 4 May 2022
EPS came in at $0.48 falling short of the estimated $0.52 by -7.69%, while revenue for the quarter reached $240.18m , beating expectations by +3.72%.
Earnings released on 23 Feb 2022
EPS came in at $0.57 surpassing the estimated $0.50 by +14.00%, while revenue for the quarter reached $270.10m , beating expectations by +1.08%.
Earnings released on 3 Nov 2021
EPS came in at $0.68 surpassing the estimated $0.45 by +51.11%, while revenue for the quarter reached $253.22m , beating expectations by +3.17%.
Earnings released on 28 Jul 2021
EPS came in at $0.52 surpassing the estimated $0.32 by +62.50%, while revenue for the quarter reached $264.48m , beating expectations by +7.96%.
LIVN Stock Performance
Access detailed LIVN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
